Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
Authors
Keywords
-
Journal
JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-06-02
DOI
10.1007/s00415-022-11197-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells
- (2022) Gianmarco Abbadessa et al. Multiple Sclerosis and Related Disorders
- Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
- (2021) Malin Boremalm et al. JOURNAL OF NEUROLOGY
- Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis
- (2021) Caroline Ruetsch-Chelli et al. Neurotherapeutics
- Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
- (2020) Adil Maarouf et al. Neurology-Neuroimmunology & Neuroinflammation
- The role of B cells in Multiple Sclerosis and related disorders
- (2020) Giancarlo Comi et al. ANNALS OF NEUROLOGY
- De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis
- (2020) Giulio Disanto et al. Multiple Sclerosis Journal
- B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis
- (2020) Nitzan Nissimov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
- (2019) Yvonne Naegelin et al. JAMA Neurology
- Anti-CD20 therapy depletes activated myelin-specific CD8+T cells in multiple sclerosis
- (2019) Joseph J. Sabatino et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
- (2019) Alexander Juto et al. Multiple Sclerosis and Related Disorders
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Reassessing B cell contributions in multiple sclerosis
- (2018) Rui Li et al. NATURE IMMUNOLOGY
- Effector T Cells in Multiple Sclerosis
- (2018) Belinda J. Kaskow et al. Cold Spring Harbor Perspectives in Medicine
- Multiple Sclerosis Pathology
- (2018) Hans Lassmann Cold Spring Harbor Perspectives in Medicine
- Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
- (2018) Gisa Ellrichmann et al. JOURNAL OF NEUROLOGY
- Recommendations for cognitive screening and management in multiple sclerosis care
- (2018) Rosalind Kalb et al. Multiple Sclerosis Journal
- Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study
- (2017) M. Cohen et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients
- (2016) Nele Claes et al. JOURNAL OF IMMUNOLOGY
- The expanding family of regulatory B cells
- (2015) Claudia Mauri et al. INTERNATIONAL IMMUNOLOGY
- OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol
- (2015) F. Cotton et al. JOURNAL OF NEURORADIOLOGY
- B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome
- (2015) M. Colucci et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
- (2014) Sandra Meyer-Moock et al. BMC Neurology
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- A new computerised cognitive test for the detection of information processing speed impairment in multiple sclerosis
- (2013) Aurélie Ruet et al. Multiple Sclerosis Journal
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
- (2013) Su-Hyun Kim et al. JAMA Neurology
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search